Evidence map›Paper›PMID 41380479›Full record

ArticleESMO open2025

Breast surgery and systemic treatment continuation for patients with de novo metastatic breast cancer and locoregional oligoprogression: a cohort study.

C Valenza, N Bianco, M Milano, D Trapani, S Di Bella, A Sciandivasci, I Minchella, C Sangalli, V Galimberti, M Intra and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

C ValenzaDivision of New Drug and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
N BiancoDivision of Medical Senology, European Institute of Oncology, IRCCS, Milan, Italy.
M MilanoDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
D TrapaniDivision of New Drug and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
S Di BellaDivision of New Drug and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
A SciandivasciDivision of Medical Senology, European Institute of Oncology, IRCCS, Milan, Italy.
I MinchellaDivision of New Drug and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.
C SangalliClinical Trial Office, European Institute of Oncology, IRCCS, Milan, Italy.
V GalimbertiDivision of Breast Surgery, European Institute of Oncology, IRCCS, Milan, Italy.
M IntraDivision of Breast Surgery, European Institute of Oncology, IRCCS, Milan, Italy.
P VeronesiDivision of Breast Surgery, European Institute of Oncology, IRCCS, Milan, Italy.
E MunzoneDivision of Medical Senology, European Institute of Oncology, IRCCS, Milan, Italy.
M ColleoniDivision of Medical Senology, European Institute of Oncology, IRCCS, Milan, Italy.
G CuriglianoDivision of New Drug and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Electronic address: giuseppe.curigliano@ieo.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe role of breast surgery in patients with de novo metastatic breast cancer (mBC) and locoregional oligoprogression, either in the breast or locoregional lymph nodes, who previously had a response to systemic treatment is unknown. This approach may allow maintenance of the same systemic treatment and prolong the time to treatment failure. PATIENTS AND

methodsWe conducted a cohort study including consecutive patients with de novo mBC, after a locoregional oligoprogression, who underwent breast surgery and continued the same systemic treatment at the European Institute of Oncology. The primary endpoint was postsurgery progression-free survival (pS-PFS).

resultsFifty-nine patients were included: 28 (47%) had hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative disease, 30 (51%) HER2-positive, and 1 (2%) triple-negative. The median pre-oligoprogression PFS was 15.2 months [95% confidence interval (CI) 12.0-18.4 months]. After a median follow-up of 54.1 months (95% CI 44.2-64.0 months), the median pS-PFSs was 15.0 months (95% CI 5.1-24.9 months), and was significantly longer in patients with HER2-positive disease or with a pre-oligoprogression PFS ≥12 months.

conclusionsThis study suggests that selected patients with de novo mBC and locoregional oligoprogression can benefit from breast surgery while maintaining the same systemic treatment, particularly in the setting of HER2-positive disease or a pre-oligoprogression PFS >1 year.

Indexed as

Breast NeoplasmsMastectomyAdultAgedCohort StudiesDisease ProgressionFemaleHumansMiddle AgedNeoplasm Metastasisbreast surgeryoligoprogressive breast cancer

Identifiers

PMID41380479
PMCPMC12754202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.